GLP-1 insurance coverage is inconsistent. Even covered patients often face prior authorization, step therapy, and formulary restrictions.
Industry NewsJune 1, 2026Editorial
Editorial disclosure: GLP-1 Price Guide is an educational health pricing resource. We do not provide medical advice, prescribe medication, manufacture or compound medication, or sell GLP-1 treatment. Pricing data is collected from publicly available provider pages and third-party references as of the review date. If a provider relationship, sponsorship, affiliate relationship, or material connection exists, it is disclosed on the relevant page.
Type 2 diabetes: Ozempic and Mounjaro often well-covered for T2D indication
Weight management: Wegovy and Zepbound coverage varies widely; many commercial plans require BMI thresholds and prior auth
Medicare: No coverage for obesity-only indication (as of 2026); covered for T2D
Medicaid: Varies by state
Why Cash-Pay Compounded Has Grown
Patients without insurance coverage or with restrictive prior auth have driven cash-pay compounded GLP-1 demand. Compounded prices ($145-$499/mo) are significantly lower than brand-name cash retail (~$1,300-$1,400/mo).
Sources reviewed
Provider pricing pages (live as of June 1, 2026)
Provider terms, refund, and support pages
Third-party pricing comparisons and analyst reports
Important medical and regulatory disclosure
Compounded semaglutide and compounded tirzepatide are not FDA-approved finished drug products. They are not the same as Ozempic, Wegovy, Mounjaro, or Zepbound. Compounded medications may be prescribed only when clinically appropriate after review by a licensed medical provider. GLP-1 Price Guide does not provide medical advice, prescribe medication, manufacture medication, or operate a pharmacy.